Hospital
Baptist Healthcare System, INC.
Baptist Healthcare System, INC. was paid $34.67M by Medicaid between Jan 2018 and Dec 2024, across 178 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoBAPTIST HEALTHCARE SYSTEM, INC.
NEW ALBANY, IN 47150
NEW ALBANY, IN 47150
33aNPI1497798847assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$34.67M
24GClaims736,142
24DCodes billed178
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#9 of 69
Median peer was paid$9.76M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CARRICO, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 87,825 | $1.43M | |
| 2019 | 88,232 | $2.89M | |
| 2020 | 76,830 | $2.90M | |
| 2021 | 102,607 | $4.64M | |
| 2022 | 134,389 | $6.51M | |
| 2023 | 137,590 | $9.06M | |
| 2024incomplete | 108,669 | $7.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 67,145 | 55,633 | $9.88M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 44,716 | 33,585 | $4.57M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 33,661 | 27,239 | $4.54M |
| 71045 | Radiologic examination, chest; single view | 6.2% | 17,758 | 14,448 | $2.13M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.0% | 23,616 | 18,389 | $1.39M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,967 | 2,465 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 7,448 | 6,130 | $948K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 6,669 | 5,606 | $871K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.4% | 7,117 | 6,485 | $826K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 27,415 | 21,878 | $729K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.1% | 7,441 | 5,935 | $725K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 6,667 | 5,201 | $562K |
166 more codes
| 62323 | 1.4% | 1,068 | $500K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 338 | $462K |
| 80050 | General health panel | 1.2% | 2,236 | $432K |
| 80053 | Comprehensive metabolic panel | 1.1% | 69,278 | $371K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 74,057 | $291K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,743 | $286K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 728 | $203K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,276 | $201K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,637 | $184K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 929 | $181K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,562 | $174K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,679 | $172K |
| 99221 | <1% | 354 | $168K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,666 | $142K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 212 | $130K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,688 | $126K |
| 84484 | <1% | 19,123 | $122K | |
| 80061 | Lipid panel | <1% | 17,227 | $122K |
| 99220 | <1% | 340 | $117K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,543 | $112K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,136 | $112K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,140 | $95K |
| 36415 | Collection of venous blood by venipuncture | <1% | 42,929 | $91K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 277 | $86K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,170 | $82K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,509 | $81K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 826 | $74K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,693 | $72K |
| 29581 | <1% | 1,049 | $69K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,410 | $63K |
| G0378 | Hospital observation service, per hour | <1% | 97 | $60K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,690 | $60K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 39 | $60K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,347 | $50K |
| 83690 | <1% | 15,004 | $50K | |
| 93017 | <1% | 537 | $48K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,253 | $46K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,939 | $45K |
| 81001 | <1% | 20,929 | $35K | |
| 81025 | <1% | 5,970 | $34K | |
| 83880 | <1% | 1,699 | $33K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 621 | $30K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 719 | $28K |
| 82607 | <1% | 3,300 | $26K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 209 | $26K |
| 84439 | <1% | 4,712 | $23K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 519 | $23K |
| 77336 | <1% | 385 | $20K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 4,493 | $20K |
| 83735 | <1% | 5,152 | $19K | |
| 20610 | <1% | 128 | $16K | |
| 97597 | <1% | 93 | $14K | |
| 81003 | <1% | 10,052 | $13K | |
| 87631 | <1% | 196 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,827 | $11K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,359 | $9K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 52 | $9K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 75 | $8K |
| 85379 | <1% | 1,163 | $8K | |
| 94060 | <1% | 159 | $7K | |
| 84425 | <1% | 511 | $7K | |
| 82043 | <1% | 2,614 | $6K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 795 | $6K |
| 64494 | <1% | 26 | $6K | |
| 82570 | <1% | 2,732 | $6K | |
| 77334 | <1% | 68 | $6K | |
| 87634 | <1% | 125 | $6K | |
| 77300 | <1% | 65 | $5K | |
| 82728 | <1% | 733 | $5K | |
| 64493 | <1% | 26 | $5K | |
| 84466 | <1% | 643 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 21 | $4K |
| 85027 | <1% | 1,231 | $4K | |
| 82962 | <1% | 2,525 | $4K | |
| 85610 | <1% | 2,022 | $4K | |
| 82948 | <1% | 1,309 | $4K | |
| 85730 | <1% | 1,242 | $4K | |
| 86140 | <1% | 1,667 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 222 | $4K |
| 87040 | <1% | 744 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 95 | $3K |
| 80074 | <1% | 191 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 274 | $3K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 5,452 | $3K |
| 83540 | <1% | 662 | $2K | |
| 80306 | <1% | 544 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $2K |
| 85652 | <1% | 1,580 | $2K | |
| 87070 | <1% | 363 | $1K | |
| 86803 | <1% | 154 | $1K | |
| 29580 | <1% | 38 | $1K | |
| 80076 | <1% | 470 | $1K | |
| 86481 | <1% | 30 | $889.39 | |
| 93922 | <1% | 21 | $845.31 | |
| 86850 | <1% | 197 | $822.24 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 306 | $774.15 |
| 83605 | <1% | 121 | $771.07 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,476 | $769.38 |
| 87081 | <1% | 199 | $742.29 | |
| 82550 | <1% | 211 | $701.31 | |
| 82077 | <1% | 64 | $590.55 | |
| 84703 | <1% | 102 | $578.85 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 23 | $554.44 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 23 | $554.44 |
| 87807 | <1% | 73 | $510.28 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,597 | $490.86 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $447.93 |
| 86901 | <1% | 197 | $442.51 | |
| 86900 | <1% | 197 | $439.06 | |
| 82746 | <1% | 45 | $420.55 | |
| 97162 | <1% | 15 | $420.42 | |
| 82164 | <1% | 53 | $387.58 | |
| 82803 | <1% | 30 | $339.37 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 28 | $319.54 |
| 83655 | <1% | 26 | $317.16 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 15 | $283.50 |
| 36600 | <1% | 30 | $283.19 | |
| 87186 | <1% | 125 | $224.94 | |
| 84145 | <1% | 23 | $217.76 | |
| 87205 | <1% | 257 | $215.45 | |
| 85007 | <1% | 110 | $208.63 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,288 | $191.25 |
| 84165 | <1% | 65 | $174.54 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 342 | $148.13 |
| 94729 | <1% | 266 | $140.62 | |
| 94664 | <1% | 30 | $124.20 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 34 | $109.23 |
| 84100 | <1% | 49 | $108.93 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,156 | $103.85 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 4,959 | $86.42 |
| 86200 | <1% | 18 | $83.99 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 24 | $74.57 |
| 85045 | <1% | 33 | $74.56 | |
| 96376 | <1% | 407 | $73.71 | |
| 80069 | <1% | 16 | $61.58 | |
| 84550 | <1% | 36 | $54.23 | |
| 84156 | <1% | 31 | $50.21 | |
| 83615 | <1% | 16 | $48.00 | |
| 86431 | <1% | 20 | $42.85 | |
| 86703 | <1% | 17 | $39.82 | |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 540 | $26.97 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,201 | $7.68 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 493 | $0.08 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,309 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 418 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 35 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 717 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 517 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 251 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 75 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 37 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 183 | $0.00 |
| C1769 | Guide wire | 0% | 24 | $0.00 |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | 0% | 16 | $0.00 |
| 0099U | 0% | 12 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 729 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 410 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 199 | $0.00 |
| 94727 | 0% | 48 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 52 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 23 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 35 | $0.00 |
| 94726 | 0% | 15 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRICO, RICHARD (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.